Modality
Fusion Protein
MOA
Anti-Tau
Target
CDK4/6
Pathway
Neuroinflam
DLBCLRett
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Jan 2026
Phase 1Current
NCT03202778
2,634 pts·DLBCL
2021-11→2026-01·Not yet recruiting
NCT07828327
2,248 pts·Rett
2020-02→TBD·Not yet recruiting
4,882 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-152mo agoInterim· DLBCL
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1
Not yet…
P1
Not yet…
Catalysts
Interim
2026-01-15 · 2mo ago
DLBCL
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03202778 | Phase 1 | DLBCL | Not yet recr... | 2634 | MRD |
| NCT07828327 | Phase 1 | Rett | Not yet recr... | 2248 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Voxamavacamten | Corcept | Approved | BET |